Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ2 | O43526 | 7/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ADRA1D | P25100 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | ADRA1B | P35368 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.54 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.44 |
| ▸ | KCNH3 | Q9ULD8 | 2/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | THPO | P40225 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29381857 | 1.00 | KCNQ2 (1.00) | KCNQ2CYP3A4ALOX15TSHRADRA1D | |
| SCHEMBL7358470 | 0.95 | KCNQ2 (0.90) | KCNQ2CYP3A4ALOX15TSHRADRA1D | |
| SCHEMBL8736261 | 0.90 | KCNQ2 (0.81) | KCNQ2CYP3A4ALOX15TSHRADRA1D | |
| SCHEMBL13002456 | 0.89 | KCNQ2 (0.79) | KCNQ2CYP3A4ALOX15TSHRADRA1D | |
| SCHEMBL8058909 | 0.87 | KCNQ2 (0.78) | KCNQ2CYP3A4ALOX15TSHRADRA1D | |
| SCHEMBL8381380 | 0.87 | KCNQ2 (0.76) | KCNQ2CYP3A4ALOX15TSHRADRA1D | |
| SCHEMBL8377502 | 0.85 | KCNQ2 (0.74) | KCNQ2CYP3A4ALOX15TSHRADRA1D | |
| Hydrochloric Acid SCHEMBL28745488 | 0.84 | KCNQ2 (0.72) | KCNQ2CYP3A4ALOX15TSHRADRA1D | |
| SCHEMBL8380614 | 0.83 | KCNQ2 (0.71) | KCNQ2CYP3A4ALOX15TSHRADRA1D | |
| SCHEMBL12998025 | 0.82 | KCNQ2 (0.68) | KCNQ2CYP3A4ALOX15TSHRADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150410-A1 | Controlled Release Ion Channel Modulator Compositions and Methods for the Treatment of Otic Disorders | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-13 | — | — | US | claimed |
| US-8399018-B2 | Controlled release ion channel modulator compositions and methods for the treatment of otic disorders | OTONOMY, INC. (US) | 2013-03-19 | — | — | US | claimed |
| US-6262081-B1 | ADMINISTERING TO THE MAMMAL A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMBINATION OF: (I) AT LEAST ONE NEUROTRANSMITTER RELEASE ENHANCER, AND (II) AT LEAST ONE ACETYLCHOLINESTERASE INHIBITOR. | DUPONT PHARMACEUTICALS COMPANY | 2001-07-17 | — | — | US | claimed |
| US-6214847-B1 | TREATMENT OF COGNITIVE OR NEUROLOGICAL DYSFUNCTION | DUPONT PHARMACEUTICALS COMPANY | 2001-04-10 | — | — | US | claimed |
| EP-1003722-A1 | CRYSTALLINE 10,10-BIS((2-FLUORO-4-PYRIDINYL)METHYL)-9(10H)-ANTHRACENONE AND AN IMPROVED PROCESS FOR PREPARING THE SAME | Du Pont Pharmaceuticals Company (US) | 2000-05-31 | — | — | EP | claimed |
| WO-1999009010-A1 | CRYSTALLINE 10,10-BIS((2-FLUORO-4-PYRIDINYL)METHYL)-9(10H)-ANTHRACENONE AND AN IMPROVED PROCESS FOR PREPARING THE SAME | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-02-25 | — | — | WO | claimed |
| US-5750528-A | Blockade of neuronal m-channels as a therapeutic approach to the treatment of neurological disease | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-05-12 | — | — | US | claimed |
| US-5594001-A | Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-01-14 | — | — | US | claimed |
| US-20250282725-A1 | KCNQ POTENTIATORS | Eii Lilly and Company | 2025-09-11 | — | — | US | disclosed |
| US-12344584-B2 | KCNQ potentiators | ELI LILLY AND COMPANY (US) | 2025-07-01 | — | — | US | disclosed |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-10-31 | — | — | US | disclosed |
| US-20240226054-A9 | AGENTS AND METHODS FOR PREVENTING AND TREATING SKELETAL MUSCLE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-07-11 | — | — | US | disclosed |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2024-04-30 | — | — | US | disclosed |
| US-20240131000-A1 | AGENTS AND METHODS FOR PREVENTING AND TREATING SKELETAL MUSCLE DISEASES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-25 | — | — | US | disclosed |
| US-5990132-A | ?CORE GROUP? TRICYCLIC RING SYSTEM OF GIVEN FORMULA A-C-B FORMED BY A AND B, 5- OR SIX MEMBERED CARBOCYCLIC, OR HETEROCYCLIC RINGS, AND THE CENTRAL SIX-MEMBERED SULFUR CONTAINING RING C; DISUBSTITUTED WITH PYRIDINE GROUPS | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1999-11-23 | — | — | US | disclosed |
| WO-1999009010-A1 | CRYSTALLINE 10,10-BIS((2-FLUORO-4-PYRIDINYL)METHYL)-9(10H)-ANTHRACENONE AND AN IMPROVED PROCESS FOR PREPARING THE SAME | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1999009010-A1 | CRYSTALLINE 10,10-BIS((2-FLUORO-4-PYRIDINYL)METHYL)-9(10H)-ANTHRACENONE AND AN IMPROVED PROCESS FOR PREPARING THE SAME | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| WO-1999009010-A1 | CRYSTALLINE 10,10-BIS((2-FLUORO-4-PYRIDINYL)METHYL)-9(10H)-ANTHRACENONE AND AN IMPROVED PROCESS FOR PREPARING THE SAME | DU PONT PHARMACEUTICALS COMPANY (US) | 1999-02-25 | — | — | WO | disclosed |
| US-5594001-A | Polycyclic systems, and derivatives thereof, as neurotransmitter release enhancers useful in the treatment of cognitive disorders | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| WO-1994024131-A1 | NOVEL POLYCYCLIC SYSTEMS, AND DERIVATIVES THEREOF, AS NEUROTRANSMITTER RELEASE ENHANCER USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250282725-A1 | KCNQ POTENTIATORS | KCNN3, KCNQ1, KCNN1 | KCNQ2 5/4885CYP3A4 2954/4885ALOX15 2723/4885 |
| US-20130150410-A1 | Controlled Release Ion Channel Modulator Compositions and Methods for the Treatment of Otic Disorders | TRPV1, ATP2A1, TRPM2 | KCNQ2 53/4885CYP3A4 4499/4885ALOX15 1644/4885 |
| US-12344584-B2 | KCNQ potentiators | KCNN3, KCNQ1, KCNN1 | KCNQ2 5/4885CYP3A4 2954/4885ALOX15 2723/4885 |
| US-20240358634-A1 | AURIS FORMULATIONS FOR TREATING OTIC DISEASES AND CONDITIONS | OTC, AQP4, SLC26A4 | KCNQ2 2082/4885CYP3A4 4486/4885ALOX15 462/4885 |
| US-11969501-B2 | Auris formulations for treating otic diseases and conditions | OTC, AQP4, SLC26A4 | KCNQ2 2082/4885CYP3A4 4486/4885ALOX15 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.